Welcome to our dedicated page for BIOLASE news (Ticker: BIOL), a resource for investors and traders seeking the latest updates and insights on BIOLASE stock.
BIOLASE Inc. (BIOL) pioneers advanced laser solutions transforming dental care through minimally invasive technologies. This dedicated news hub provides investors and dental professionals with essential updates on product innovations, financial performance, and clinical developments.
Access real-time announcements including earnings reports, FDA clearances, partnership agreements, and technological breakthroughs. Our curated collection ensures transparent access to material events shaping BIOLASE's position in the $7B dental laser market.
Key updates cover regulatory milestones, patent filings, clinical trial results, and executive commentary. Discover how BIOLASE's Waterlase technology and Epic X platform continue redefining standards in laser dentistry through reduced recovery times and enhanced precision.
Bookmark this page for structured access to verified corporate communications. Monitor BIOLASE's progress in expanding global adoption of dental lasers while maintaining compliance with SEC disclosure requirements and medical device regulations.
BIOLASE, Inc. (NASDAQ: BIOL) urges stockholders to vote 'FOR' all proposals at the upcoming 2021 annual meeting scheduled for May 26, 2021. Key proposals include the amendment to increase shares available for the 2018 Long-Term Incentive Plan, a reverse stock split to ensure continued Nasdaq listing, and increasing authorized shares for future corporate flexibility. The Board emphasizes that these actions will attract institutional investors, retain employees, and promote liquidity. The company focuses on strategic growth and enhancing shareholder value post-COVID-19.
BIOLASE (NASDAQ: BIOL) and EdgeEndo announced a partnership to develop the EdgePRO Laser-Assisted Microfluidic Irrigation device. This device aims to enhance endodontic cleaning and disinfection techniques, building upon BIOLASE's established technology that improves debridement and biofilm removal. A premarket notification to the FDA is anticipated in Q2 2021, with the device currently unavailable for sale in the U.S. The collaboration leverages both companies' strengths, aiming to improve patient outcomes and facilitate broader usage of laser technology in dentistry.
BIOLASE, Inc. (NASDAQ: BIOL) has launched a pilot program with Einstein Healthcare Network's endodontics residency to train residents using Waterlase dental lasers. The initiative aims to enhance residents' practical skills, ensuring their readiness to implement advanced laser techniques in future practices. This collaboration is part of BIOLASE's commitment to advancing dentistry and improving patient care through innovative technologies. The endodontics residency is a 24-month program, preparing graduates for various professional roles in dentistry.
BIOLASE, Inc. (NASDAQ: BIOL) reported its financial results for Q4 and the full year 2020, revealing a 31% sequential revenue growth to $8.5 million. Despite COVID-19 challenges, U.S. revenue showed resilience, particularly from new users (78%) and dental specialists (40%). Cash reserves reached $17.9 million, boosted by a recent $14.4 million placement. However, year-over-year revenue dropped 17%. The company projects a 65% revenue growth for Q1 2021 compared to Q1 2020.
BIOLASE, Inc. (NASDAQ: BIOL) will release its fourth quarter and full-year 2020 financial results on March 25, 2021, after the U.S. markets close. A conference call and webcast will be held at 4:30 p.m. ET to discuss the results. Interested participants can join by dialing (800) 353-6461 in the U.S./Canada or (334) 323-0501 internationally, using Conference ID 7623727. An audio archive of the webcast will be available for 30 days on the BIOLASE website. BIOLASE is a leader in laser systems for dentistry, with over 41,200 systems sold worldwide.
BIOLASE, Inc. (NASDAQ: BIOL) announced that John Beaver, President and CEO, will present at Maxim Group's Inaugural 2021 Emerging Growth Virtual Investor Conference from March 17-19, 2021. Beaver will join a fireside chat with analyst Anthony Vendetti on March 17 from 10:30 am to 11:00 am Eastern Time. Investors can register for the conference here. BIOLASE specializes in laser systems for dental and medical applications, having sold over 41,200 systems worldwide.
BIOLASE, Inc. (NASDAQ: BIOL) has established the Waterlase Perio Academy (WPA) to enhance periodontal and implant services among clinicians. The WPA aims to leverage laser technology for improved patient outcomes through peer-led learning and mentorship by industry experts. Members will benefit from online discussions, case reviews, and real-time training on new procedures. The initiative responds to the rising incidence of periodontal diseases associated with systemic health issues. BIOLASE's commitment aligns with advancing dental technologies and improving patient care.
BIOLASE, the global leader in dental lasers, announced that CEO John Beaver will provide an overview of the company at the H.C. Wainwright Global Life Sciences Investor Conference on March 9-10, 2021. The presentation will highlight recent progress and achievements. Investors can schedule one-on-one meetings with BIOLASE executives. The formal presentation will be available on the company’s investor relations webpage. BIOLASE is known for its innovative laser systems, having sold over 41,200 systems worldwide, enhancing dental care with patented technologies.
BIOLASE, Inc. (NASDAQ: BIOL) has appointed John R. Beaver as President and CEO, effective February 23, 2021. Beaver, previously EVP and COO, succeeds Todd Norbe, who resigned to pursue other interests. Beaver's hands-on experience in the dental industry and financial expertise are expected to drive growth, with the company boasting a cash position of approximately $40 million. The leadership change comes at a critical time as BIOLASE aims to support dental practices in adapting to challenges posed by the COVID-19 pandemic.
BIOLASE, Inc. (NASDAQ: BIOL) has completed a bought deal offering of 14 million shares at $1.03 per share, raising approximately $14.4 million. This increase in cash brings their total to over $40 million, facilitating the execution of their growth strategy. The offering was met with strong interest from healthcare-focused institutional investors. Joint-bookrunning managers included Maxim Group LLC, The Benchmark Company, and Colliers Securities LLC. The shares were offered under a previously effective registration statement with the SEC.
FAQ
What is the current stock price of BIOLASE (BIOL)?
What is the market cap of BIOLASE (BIOL)?
